A clinical-stage biotechnology company
PEP-Therapy is a French biotechnology company developing first-in-class peptides as targeted therapies in oncology.
PEP-010, first drug candidate, is a pro-apoptotic agent which has demonstrated anti-tumor efficacy in several pre-clinical models and a good safety profile.
PEP-010 is currently evaluated in a Phase Ia/b clinical trial in patients with recurrent and/or metastatic solid tumors. The trial is conducted in partnership with two leading European cancer centers, Institut Curie and Gustave Roussy, and at François Baclesse center.
Backed by international investors
PEP-Therapy, which was founded in 2014 and builds on research from Sorbonne University and Institut Curie, is backed by international investors: Seventure Partners, Italian Angels for Growth, Doorway, Magna Capital Partners, Anaxago, i&i Prague, Business Angels des Grandes Ecoles (BAdGE), and Jérôme Majoie (former Managing Director of Laboratoires Fournier affiliates (USA, UK, Sweden, Japan), CEO of La Fondation Fournier-Majoie).